

List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/1980625/roberta-ruda-publications-by-citations.pdf>  
**Version:** 2024-04-09

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.  
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

144 papers	4,558 citations	35 h-index	66 g-index
151 ext. papers	5,962 ext. citations	4.6 avg, IF	5.53 L-index

#	Paper	IF	Citations
144	Chemoimmunotherapy with methotrexate, cytarabine, thiopeta, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial. <i>Lancet Haematology, the</i> , <b>2016</b> , 3, e217-27	14.6	288
143	Management of brain metastases. <i>Journal of Neurology</i> , <b>2002</b> , 249, 1357-69	5.5	277
142	Diagnosis and treatment of primary CNS lymphoma in immunocompetent patients: guidelines from the European Association for Neuro-Oncology. <i>Lancet Oncology, The</i> , <b>2015</b> , 16, e322-32	21.7	247
141	Diagnosis and treatment of brain metastases from solid tumors: guidelines from the European Association of Neuro-Oncology (EANO). <i>Neuro-Oncology</i> , <b>2017</b> , 19, 162-174	1	244
140	Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study. <i>Lancet, The</i> , <b>2017</b> , 390, 1645-1653	40	225
139	EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood. <i>Nature Reviews Clinical Oncology</i> , <b>2021</b> , 18, 170-186	19.4	204
138	Seizures in low-grade gliomas: natural history, pathogenesis, and outcome after treatments. <i>Neuro-Oncology</i> , <b>2012</b> , 14 Suppl 4, iv55-64	1	162
137	PCV chemotherapy for recurrent oligodendrogliomas and oligoastrocytomas. <i>Neurosurgery</i> , <b>1998</b> , 43, 1066-73	3.2	142
136	European Association for Neuro-Oncology (EANO) guidelines for palliative care in adults with glioma. <i>Lancet Oncology, The</i> , <b>2017</b> , 18, e330-e340	21.7	138
135	Epilepsy and brain tumors. <i>Current Opinion in Oncology</i> , <b>2010</b> , 22, 611-20	4.2	118
134	Leptomeningeal metastasis: a Response Assessment in Neuro-Oncology critical review of endpoints and response criteria of published randomized clinical trials. <i>Neuro-Oncology</i> , <b>2014</b> , 16, 1176-85	15	116
133	Brain metastases: current management and new developments. <i>Current Opinion in Oncology</i> , <b>2008</b> , 20, 676-84	4.2	116
132	Regorafenib compared with lomustine in patients with relapsed glioblastoma (REGOMA): a multicentre, open-label, randomised, controlled, phase 2 trial. <i>Lancet Oncology, The</i> , <b>2019</b> , 20, 110-119	21.7	116
131	Ependymomas in adults. <i>Current Neurology and Neuroscience Reports</i> , <b>2010</b> , 10, 240-7	6.6	106
130	Leptomeningeal metastases: a RANO proposal for response criteria. <i>Neuro-Oncology</i> , <b>2017</b> , 19, 484-492	1	101
129	EANO guidelines for the diagnosis and treatment of ependymal tumors. <i>Neuro-Oncology</i> , <b>2018</b> , 20, 445-456	15	100
128	Combination of neoadjuvant chemotherapy followed by surgical resection as a new strategy for WHO grade II gliomas: a study of cognitive status and quality of life. <i>Journal of Neuro-Oncology</i> , <b>2012</b> , 106, 353-66	4.8	82

127	EPID-27GLIOSTY (GLIOBLASTOMA REGISTRY) OF THE AINO (ITALIAN ASSOCIATION OF NEURO-ONCOLOGY): ANALYSIS OF FACTORS INFLUENCING SURVIVAL IN GLIOBLASTOMA PATIENTS RECEIVING THE NITROSOUREA FOTEMUSTINE AT FIRST PROGRESSION FOLLOWING THE STUPP REGIMEN. <i>Neuro-Oncology</i> , <b>2015</b> , 17, v84.1-v84	1	78
126	41. PROGNOSTIC VALIDATION OF THE EANO ESMO CLASSIFICATION OF LEPTOMENINGEAL METASTASIS. <i>Neuro-Oncology Advances</i> , <b>2020</b> , 2, ii7-ii8	0.9	78
125	Mechanisms and Therapy for Cancer Metastasis to the Brain. <i>Frontiers in Oncology</i> , <b>2018</b> , 8, 161	5.3	72
124	Ependymomas of the adult: molecular biology and treatment. <i>Current Opinion in Neurology</i> , <b>2008</b> , 21, 754-61	7.1	68
123	Liquid biopsy in central nervous system metastases: a RANO review and proposals for clinical applications. <i>Neuro-Oncology</i> , <b>2019</b> , 21, 571-584	1	67
122	Seizure control as a new metric in assessing efficacy of tumor treatment in low-grade glioma trials. <i>Neuro-Oncology</i> , <b>2017</b> , 19, 12-21	1	65
121	Targeted therapy in brain metastasis. <i>Current Opinion in Oncology</i> , <b>2012</b> , 24, 679-86	4.2	61
120	Seizure control following radiotherapy in patients with diffuse gliomas: a retrospective study. <i>Neuro-Oncology</i> , <b>2013</b> , 15, 1739-49	1	60
119	Prognostic value of molecular and imaging biomarkers in patients with supratentorial glioma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2017</b> , 44, 1155-1164	8.8	58
118	Bevacizumab and fotemustine for recurrent glioblastoma: a phase II study of AINO (Italian Association of Neuro-Oncology). <i>Journal of Neuro-Oncology</i> , <b>2014</b> , 116, 533-41	4.8	58
117	Brain metastases from unknown primary tumour: a prospective study. <i>Journal of Neurology</i> , <b>2001</b> , 248, 394-8	5.5	55
116	The RANO Leptomeningeal Metastasis Group proposal to assess response to treatment: lack of feasibility and clinical utility and a revised proposal. <i>Neuro-Oncology</i> , <b>2019</b> , 21, 648-658	1	50
115	Amino acid positron emission tomography to monitor chemotherapy response and predict seizure control and progression-free survival in WHO grade II gliomas. <i>Neuro-Oncology</i> , <b>2016</b> , 18, 744-51	1	46
114	Management of brain metastases according to molecular subtypes. <i>Nature Reviews Neurology</i> , <b>2020</b> , 16, 557-574	15	44
113	Kinetics of tumor size and peritumoral brain edema before, during, and after systemic therapy in recurrent WHO grade II or III meningioma. <i>Neuro-Oncology</i> , <b>2016</b> , 18, 401-7	1	41
112	Diagnosis and treatment patterns for patients with leptomeningeal metastasis from solid tumors across Europe. <i>Journal of Neuro-Oncology</i> , <b>2017</b> , 133, 419-427	4.8	38
111	MGMT promoter methylation in plasma of glioma patients receiving temozolomide. <i>Journal of Neuro-Oncology</i> , <b>2014</b> , 117, 347-57	4.8	38
110	Neurologic complications of chemotherapy and other newer and experimental approaches. <i>Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn</i> , <b>2014</b> , 121, 1199-218	3	38

109	Predictors of survival and effect of short (40 Gy) or standard-course (60 Gy) irradiation plus concomitant temozolomide in elderly patients with glioblastoma: a multicenter retrospective study of AINO (Italian Association of Neuro-Oncology). <i>Journal of Neuro-Oncology</i> , <b>2015</b> , 125, 359-67	4.8	34
108	Second-line treatment with carboplatin for recurrent or progressive oligodendroglial tumors after PCV (procarbazine, lomustine, and vincristine) chemotherapy: a phase II study. <i>Cancer</i> , <b>2004</b> , 100, 807-13	6.4	33
107	Fusions in Central Nervous System Tumors: A Rare, but Worthy Target. <i>International Journal of Molecular Sciences</i> , <b>2020</b> , 21,	6.3	28
106	What is New in the Management of Epilepsy in Gliomas?. <i>Current Treatment Options in Neurology</i> , <b>2015</b> , 17, 351	4.4	27
105	Better see to better agree: phosphohistone H3 increases interobserver agreement in mitotic count for meningioma grading and imposes new specific thresholds. <i>Neuro-Oncology</i> , <b>2015</b> , 17, 663-9	1	27
104	Temozolomide as salvage treatment for recurrent intracranial ependymomas of the adult: a retrospective study. <i>Neuro-Oncology</i> , <b>2016</b> , 18, 261-8	1	25
103	Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): second interim analysis of a randomised, open-label, phase 3 study. <i>Lancet Oncology</i> , <b>2021</b> , 22, 813-823	21.7	24
102	Lacosamide in patients with gliomas and uncontrolled seizures: results from an observational study. <i>Journal of Neuro-Oncology</i> , <b>2018</b> , 136, 105-114	4.8	20
101	Gliomatosis cerebri: a review. <i>Current Treatment Options in Neurology</i> , <b>2014</b> , 16, 273	4.4	20
100	Evaluation of low-grade glioma structural changes after chemotherapy using DTI-based histogram analysis and functional diffusion maps. <i>European Radiology</i> , <b>2016</b> , 26, 1263-73	8	19
99	Malignant spinal cord compression in cerebral glioblastoma multiforme: a multicenter case series and review of the literature. <i>Journal of Neuro-Oncology</i> , <b>2012</b> , 110, 221-6	4.8	19
98	Is supratotal resection achievable in low-grade gliomas? Feasibility, putative factors, safety, and functional outcome. <i>Journal of Neurosurgery</i> , <b>2019</b> , 132, 1692-1705	3.2	18
97	New developments in the treatment of malignant gliomas. <i>Expert Review of Neurotherapeutics</i> , <b>2007</b> , 7, 1313-26	4.3	17
96	Prognostic validation and clinical implications of the EANO ESMO classification of leptomeningeal metastasis from solid tumors. <i>Neuro-Oncology</i> , <b>2021</b> , 23, 1100-1112	1	17
95	A molecular signature associated with prolonged survival in glioblastoma patients treated with regorafenib. <i>Neuro-Oncology</i> , <b>2021</b> , 23, 264-276	1	17
94	Caveolin 1 expression independently predicts shorter survival in oligodendrogliomas. <i>Journal of Neuropathology and Experimental Neurology</i> , <b>2009</b> , 68, 425-31	3.1	16
93	Effectiveness and tolerability of lacosamide as add-on therapy in patients with brain tumor-related epilepsy: Results from a prospective, noninterventional study in European clinical practice (VIBES). <i>Epilepsia</i> , <b>2020</b> , 61, 647-656	6.4	15
92	New chemotherapy options for the treatment of malignant gliomas. <i>Anti-Cancer Drugs</i> , <b>2007</b> , 18, 621-32	2.4	15

91	Ki-67 proliferation index but not mitotic thresholds integrates the molecular prognostic stratification of lower grade gliomas. <i>Oncotarget</i> , <b>2016</b> , 7, 21190-8	3.3	15
90	Neoplastic meningitis in solid tumors: from diagnosis to personalized treatments. <i>Therapeutic Advances in Neurological Disorders</i> , <b>2018</b> , 11, 1756286418759618	6.6	13
89	Efficacy of initial temozolomide for high-risk low grade gliomas in a phase II AINO (Italian Association for Neuro-Oncology) study: a post-hoc analysis within molecular subgroups of WHO 2016. <i>Journal of Neuro-Oncology</i> , <b>2019</b> , 145, 115-123	4.8	12
88	Meningiomas after cranial radiotherapy for childhood cancer: a single institution experience. <i>Journal of Cancer Research and Clinical Oncology</i> , <b>2015</b> , 141, 1277-82	4.9	12
87	Meningeal carcinomatosis underdiagnosis and overestimation: incidence in a large consecutive and unselected population of breast cancer patients. <i>BMC Cancer</i> , <b>2015</b> , 15, 1021	4.8	12
86	Low-grade gliomas. <i>Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn</i> , <b>2012</b> , 105, 437-50	5.0	12
85	Is surgical resection useful in elderly newly diagnosed glioblastoma patients? Outcome evaluation and prognostic factors assessment. <i>Acta Neurochirurgica</i> , <b>2018</b> , 160, 1779-1787	3	12
84	Italian consensus and recommendations on diagnosis and treatment of low-grade gliomas. An intersociety (SINch/AINO/SIN) document. <i>Journal of Neurosurgical Sciences</i> , <b>2020</b> , 64, 313-334	1.3	11
83	Liquoral liquid biopsy in neoplastic meningitis enables molecular diagnosis and mutation tracking: a proof of concept. <i>Neuro-Oncology</i> , <b>2017</b> , 19, 451-453	1	10
82	Rare glial tumors. <i>Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn</i> , <b>2016</b> , 134, 399-415	5.0	10
81	Epilepsy in brain metastasis: an emerging entity. <i>Current Treatment Options in Neurology</i> , <b>2020</b> , 22, 6	4.4	9
80	Treatment of brain metastasis: current status and future directions. <i>Current Opinion in Oncology</i> , <b>2016</b> , 28, 502-510	4.2	9
79	Pharmacologic therapies for malignant glioma: a guide for clinicians. <i>CNS Drugs</i> , <b>2014</b> , 28, 1127-37	6.7	9
78	Antiangiogenic therapy of brain tumors: the role of bevacizumab. <i>Neurological Sciences</i> , <b>2014</b> , 35, 507-14	5.5	9
77	Overview on current treatment standards in high-grade gliomas. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2018</b> , 62, 225-238	1.4	9
76	Non-IDH1-R132H IDH1/2 mutations are associated with increased DNA methylation and improved survival in astrocytomas, compared to IDH1-R132H mutations. <i>Acta Neuropathologica</i> , <b>2021</b> , 141, 945-957	14.3	9
75	Pathological prognostic markers in central nervous system solitary fibrous tumour/hemangiopericytoma: Evidence from a small series. <i>PLoS ONE</i> , <b>2018</b> , 13, e0203570	3.7	9
74	Lower Grade Gliomas: Relationships Between Metabolic and Structural Imaging with Grading and Molecular Factors. <i>World Neurosurgery</i> , <b>2019</b> , 126, e270-e280	2.1	8

73	Controversies in management of low-grade gliomas in light of new data from clinical trials. <i>Neuro-Oncology</i> , <b>2017</b> , 19, 143-144	1	8
72	Prognostic Characterization of Higher-Grade Meningiomas: A Histopathological Score to Predict Progression and Outcome. <i>Journal of Neuropathology and Experimental Neurology</i> , <b>2019</b> , 78, 248-256	3.1	8
71	Prognostic significance of genome-wide DNA methylation profiles within the randomized, phase 3, EORTC CATNON trial on non-1p/19q deleted anaplastic glioma. <i>Neuro-Oncology</i> , <b>2021</b> , 23, 1547-1559	1	7
70	Point/Counterpoint: Is stereotactic radiosurgery needed following resection of brain metastasis?. <i>Neuro-Oncology</i> , <b>2016</b> , 18, 12-5	1	6
69	Intrathecal liposomal cytarabine in combination with temozolomide in low-grade oligoastrocytoma with leptomeningeal dissemination. <i>Journal of Neuro-Oncology</i> , <b>2010</b> , 97, 439-44	4.8	6
68	Management of Brain and Leptomeningeal Metastases from Breast Cancer. <i>International Journal of Molecular Sciences</i> , <b>2020</b> , 21,	6.3	6
67	Different Timing to Use Bevacizumab in Patients with Recurrent Glioblastoma: Early Delayed Administration. <i>Anticancer Research</i> , <b>2018</b> , 38, 5877-5881	2.3	6
66	Dabrafenib treatment in a patient with BRAF V600E ganglioglioma: circulating exosome-derived cancer RNA supports treatment choice and clinical monitoring. <i>Neuro-Oncology</i> , <b>2019</b> , 21, 1610-1611	1	5
65	Nocardia abscesses mimicking tumor progression in gliomatosis cerebri responding to temozolomide. <i>Journal of Neuro-Oncology</i> , <b>2015</b> , 121, 225-7	4.8	5
64	Phosphorylated Acetyl-CoA Carboxylase Is Associated with Clinical Benefit with Regorafenib in Relapsed Glioblastoma: REGOMA Trial Biomarker Analysis. <i>Clinical Cancer Research</i> , <b>2020</b> , 26, 4478-4484 <sup>12.9</sup>		5
63	Extent of surgery in low-grade gliomas: an old question in a new context. <i>Neuro-Oncology</i> , <b>2018</b> , 20, 6-7	1	5
62	Response to combined radiotherapy and chemotherapy of a leptomeningeal spread from choroid plexus carcinoma: case report. <i>Neurological Sciences</i> , <b>2015</b> , 36, 639-41	3.5	5
61	Successful use of bevacizumab in an adult primary diffuse leptomeningeal glioneuronal tumor. <i>Journal of Neurosurgical Sciences</i> , <b>2018</b> , 62, 229-232	1.3	5
60	Intracranial Meningiomas: A Systematic Analysis of Prognostic Factors for Recurrence in a Large Single Institution Surgical Series. <i>World Neurosurgery</i> , <b>2019</b> , 123, e273-e279	2.1	5
59	What Have We Learned from Recent Clinical Studies in Low-Grade Gliomas?. <i>Current Treatment Options in Neurology</i> , <b>2018</b> , 20, 33	4.4	5
58	Molecularly based management of gliomas in clinical practice. <i>Neurological Sciences</i> , <b>2015</b> , 36, 1551-7	3.5	4
57	Imaging and clinical end points in brain metastases trials. <i>CNS Oncology</i> , <b>2017</b> , 6, 243-246	4	4
56	Rare Primary Central Nervous System Tumors in Adults: An Overview. <i>Frontiers in Oncology</i> , <b>2020</b> , 10, 996	5.3	4

55	Patient-reported outcomes in a phase II randomised study of regorafenib compared with lomustine in patients with relapsed glioblastoma (the REGOMA trial). <i>European Journal of Cancer</i> , <b>2021</b> , 155, 179-190	3.5	4
54	Temozolomide for recurrent meningiomas: a case-report with unexpected clinical and radiological response. <i>Journal of Neuro-Oncology</i> , <b>2016</b> , 127, 201-3	4.8	3
53	Neuro-oncology perspective of treatment options in metastatic breast cancer. <i>Future Oncology</i> , <b>2018</b> , 14, 1765-1774	3.6	3
52	Neuro-oncology: new insights and advances in treatment. <i>Lancet Neurology</i> , <b>2008</b> , 7, 14-6	24.1	3
51	Phase II trial of dose-dense temozolomide as initial treatment for progressive low-grade oligodendroglial tumors: A multicentric study of the Italian Association of Neuro-Oncology (AINO).. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 2037-2037	2.2	3
50	REGOMA: A randomized, multicenter, controlled open-label phase II clinical trial evaluating regorafenib (REG) activity in relapsed glioblastoma (GBM) patients (PTS).. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, TPS2085-TPS2085	2.2	3
49	Updated results of REGOMA: A randomized, multicenter, controlled open-label phase II clinical trial evaluating regorafenib in relapsed glioblastoma (GBM) patients (PTS).. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 2047-2047	2.2	3
48	Blood-Brain Barrier in Brain Tumors: Biology and Clinical Relevance. <i>International Journal of Molecular Sciences</i> , <b>2021</b> , 22,	6.3	3
47	Strategies to prevent brain metastasis. <i>Current Opinion in Oncology</i> , <b>2019</b> , 31, 493-500	4.2	3
46	Complete response of spinal metastases from non-small cell lung cancer with ALK inhibitors. <i>Neurology</i> , <b>2019</b> , 93, 217-219	6.5	2
45	New developments and new dilemmas in lower-grade gliomas. <i>Neuro-Oncology</i> , <b>2019</b> , 21, 828-829	1	2
44	Is chemotherapy alone an option as initial treatment for low-grade oligodendrogliomas?. <i>Current Opinion in Neurology</i> , <b>2020</b> , 33, 707-715	7.1	2
43	Health-related quality of life (HRQoL) evaluation in the REGOMA trial: A randomized, phase II clinical trial analyzing regorafenib activity in relapsed glioblastoma patients.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 2045-2045	2.2	2
42	Depatuxizumab mafodotin (Depatux-M) plus temozolomide (TMZ) in recurrent glioblastoma patients: Real-world experience from a multicenter study of Italian Association of Neuro-Oncology (AINO).. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 2544-2544	2.2	2
41	Brain Metastasis from Unknown Primary Tumour: Moving from Old Retrospective Studies to Clinical Trials on Targeted Agents. <i>Cancers</i> , <b>2020</b> , 12,	6.6	2
40	Medulloblastoma of the adult: results from a multicenter retrospective study by AINO (Italian Association of Neuro-Oncology) and SIN (Italian Society of Neurology). <i>Neurological Sciences</i> , <b>2021</b> , 42, 665-671	3.5	2
39	Single-agent Bevacizumab in Recurrent Glioblastoma After Second-line Chemotherapy With Fotemustine: The Experience of the Italian Association of Neuro-Oncology. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , <b>2018</b> , 41, 1272-1275	2.7	2
38	Natural History and Spontaneous Prognostic Factors <b>2013</b> , 265-275		2



37	A survey on clinical pathways of patients with epilepsy and cerebrovascular diseases or brain tumors. <i>Neurological Sciences</i> , <b>2020</b> , 41, 1507-1511	3.5	1
36	Reversible disconnection syndrome in a case of acute tumefactive demyelinating lesion: a PET study. <i>Neurological Sciences</i> , <b>2016</b> , 37, 2019-2023	3.5	1
35	Solitary brain metastasis as first manifestation of small-cell parotid gland carcinoma with high sensitivity to temozolomide therapy on basis of tumor O6-methylguanine-DNA-methyltransferase expression. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, e394-7	2.2	1
34	Ependymomas, neuronal and mixed neuronal-glial tumors, dysembroblastic neuroepithelial tumors, pleomorphic xanthoastrocytomas, and pilocytic astrocytomas. <i>Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn</i> , <b>2012</b> , 105, 551-67	3	1
33	NCOG-02. PROGNOSTIC VALIDATION OF THE EANO ESMO CLASSIFICATION OF LEPTOMENINGEAL METASTASIS. <i>Neuro-Oncology</i> , <b>2020</b> , 22, ii129-ii129	1	1
32	Systemic Therapy for Lung Cancer Brain Metastases. <i>Current Treatment Options in Oncology</i> , <b>2021</b> , 22, 110	5.4	1
31	Current clinical management of elderly patients with glioma. <i>Expert Review of Anticancer Therapy</i> , <b>2020</b> , 20, 1037-1048	3.5	1
30	Perspectives of Personalized Chemotherapy of Gliomas Based on Molecular Tumor Profiling. <i>Progress in Neurological Surgery</i> , <b>2018</b> , 31, 168-179	1.4	0
29	Prescription preferences of antiepileptic drugs in brain tumor patients: An international survey among EANO members.. <i>Neuro-Oncology Practice</i> , <b>2022</b> , 9, 105-113	2.2	0
28	Spinal melanocytoma with leptomeningeal spread and long survival following surgery and chemotherapy. <i>Journal of Neurosurgical Sciences</i> , <b>2018</b> , 62, 375-378	1.3	0
27	Adult brainstem glioma: a multicentre retrospective analysis of 47 Italian patients. <i>Neurological Sciences</i> , <b>2021</b> , 42, 1879-1886	3.5	0
26	Adjuvant chemotherapy after severe myelotoxicity during chemoradiation phase in malignant gliomas. Is it feasible? Results from IAINO study (Italian Association for Neuro-Oncology). <i>Journal of Neurology</i> , <b>2021</b> , 268, 2866-2875	5.5	0
25	Ependymoma: Evaluation and Management Updates.. <i>Current Oncology Reports</i> , <b>2022</b> , 1	6.3	0
24	Clinical Concepts of Brain Tumors <b>2019</b> , 37-51		
23	Gender issues from the perspective of health-care professionals in Neuro-oncology: an EANO and EORTC Brain Tumor Group survey. <i>Neuro-Oncology Practice</i> , <b>2020</b> , 7, 249-259	2.2	
22	Long-term survival of a sacro-coccygeal myxopapillary ependymoma with extra-neural metastases: case report and review of the literature. <i>Neurological Sciences</i> , <b>2020</b> , 41, 1955-1957	3.5	
21	Brain Metastasis as Complication of Systemic Cancers <b>2018</b> , 57-79		
20	Spinal epidural metastases <b>2016</b> , 596-598		



- 19 NIMG-53. GLUTAMATE/GABA RATIO ON MRS IS ELEVATED IN PATIENTS WITH LOWER GRADE GLIOMAS AND SEIZURES. *Neuro-Oncology*, **2020**, 22, ii159-ii160 1
- 18 SURG-10. PROGNOSTIC IMPORTANCE OF THE EXTENT OF RESECTION IN IDH-WILD TYPE GRADE II ASTROCYTOMAS ACCORDING TO PTERT MUTATION. *Neuro-Oncology*, **2020**, 22, ii205-ii205 1
- 17 IDH-wild type low grade gliomas: An AINO (Italian Association of Neuro-Oncology) retrospective study.. *Journal of Clinical Oncology*, **2018**, 36, 2050-2050 2.2
- 16 Validation and revision of the RANO Leptomeningeal Metastasis Group scorecard for response assessment.. *Journal of Clinical Oncology*, **2019**, 37, e13546-e13546 2.2
- 15 Epilepsy in CNS Metastases **2020**, 117-125
- 14 Prevention Strategies for Brain Metastasis **2020**, 397-406
- 13 Temozolomide (TMZ) and radiation therapy (RT) combination in elderly patients with glioblastoma: A multicenter retrospective study of AINO (Italian Association of Neuro-Oncology).. *Journal of Clinical Oncology*, **2015**, 33, e13003-e13003 2.2
- 12 GLIOSTRY (GLIOblastoma regiSTRY) of the AINO (Italian Association of Neuro-Oncology): Analysis of factors influencing survival in glioblastoma patients receiving the nitrosourea fotemustine at first relapse following Stupp regimen.. *Journal of Clinical Oncology*, **2015**, 33, 2054-2054 2.2
- 11 Is there a Role for Bevacizumab in Non-Glial Tumors?. *Current Drug Targets*, **2015**, 16, 684-8 3
- 10 Does the duration of adjuvant temozolomide impact survival in glioblastoma patients? A retrospective analysis from an Italian registry (GLIOSTRY).. *Journal of Clinical Oncology*, **2016**, 34, 2047-2047 2.2
- 9 Natural History and Spontaneous Prognostic Factors **2017**, 307-322
- 8 A phase II trial of temozolomide (TMZ) 1 week on/1 week off as initial treatment for high risk low grade oligodendroglial tumors: An AINO (Italian Association for Neuro-Oncology) study.. *Journal of Clinical Oncology*, **2017**, 35, 2026-2026 2.2
- 7 Does an optimal management of brain metastases from oncogenic-driver non-small cell lung cancer exist?. *Neuro-Oncology*, **2020**, 22, 171-172 1
- 6 Subependymal Giant Cell Astrocytomas (SEGAs): a Model of Targeting Tumor Growth and Epilepsy. *Current Treatment Options in Neurology*, **2021**, 23, 1 4.4
- 5 Prognostic factors in leptomeningeal metastases. *Neuro-Oncology*, **2021**, 23, 1208-1209 1
- 4 BMET-18. DIAGNOSIS AND TREATMENT PATTERNS FOR PATIENTS WITH LEPTOMENINGEAL METASTASIS FROM SOLID TUMORS ACROSS EUROPE. *Neuro-Oncology*, **2016**, 18, vi30-vi30 1
- 3 Does an optimum treatment for high-risk low-grade gliomas exist?. *Lancet Oncology, The*, **2016**, 17, 1467-1469 1.4
- 2 Evidence-based approaches to chemotherapy for gliomas **2021**, 38-52

- 1 Definition of the Prognostic Role of MGMT Promoter Methylation Value by Pyrosequencing in Newly Diagnosed IDH Wild-Type Glioblastoma Patients Treated with Radiochemotherapy: A Large Multicenter Study. *Cancers*, **2022**, 14, 2425 6.6